Skip to Main Content

Paper Details

Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains.
Oncogene
15
2020
-, BRAF, BRAF dimer interface, BRAF fusion oncoprotein, BRAF fusions, BRAF intron 1, BRAF moiety, BRAF protein, BRAF serine/threonine kinase, BRAFE1, CD8, ERK, MEK, N, PLX8394, RAS binding domain, RNA, TTYH3, TTYH3 moiety, amino acids, calcium, cancers, chloride, exon 1, full-length BRAF, full-length TTYH3, glioblastoma multiforme, patient, serine, sorafenib, threonine, trametinib
Author NameAffiliation
Peter Horak
Peter Horak
Simon Kreutzfeldt
Simon Kreutzfeldt
Barbara HutterGerman Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg
Barbara HutterGerman Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg
Sebastian UhrigGerman Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg
Sebastian UhrigHeidelberg University
Olaf Neumann
Olaf NeumannInstitute of Pathology, Heidelberg University Hospital
Christof von Kalle
Albrecht Stenzinger
Albrecht StenzingerInstitute of Pathology, Heidelberg University Hospital
Benedikt BrorsGerman Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg
Benedikt Brors
Benedikt BrorsGerman Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg
Benedikt Brors
Stefan Fr??hling
Stefan Fr??hling
  • 1 - 19

Datasets

Release 1.2